Topical Lactobacillus Reuteri DSM 17938 to Evaluate Safety and Efficacy on Children With Mild or Moderate Atopic Dermatitis
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ADreuteri
Most Recent Events
- 16 Mar 2020 Status changed from not yet recruiting to recruiting.
- 17 Feb 2020 New trial record